DISEASE MODELING OF ALCOHOL RELATED HEPATOCELLULAR CARCINOMA USING PATIENT IPSCS

使用患者 IPSCS 对酒精相关肝细胞癌进行疾病建模

基本信息

  • 批准号:
    8209222
  • 负责人:
  • 金额:
    $ 23.58万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-01-01 至 2013-12-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Recent progress in human embryonic stem cell (ESC) and induced pluripotent stem cell (iPSC) research opens up unprecedented opportunities for the development of new strategies to repair and replace organs including liver. It is also highly desirable to establish disease models using patient specific iPS cells derived from the diseased tissues that contain somatic mutations which are not present in other tissues or in healthy individuals. Hepatocarcinogenesis is considered as a multi-step process involving a number of different genetic alterations caused by environmental factors such as alcohol. The accumulated effects ultimately lead to malignant transformation of hepatocytes. The molecular events underlying each step of the process are not fully understood and better model systems are needed to delineate the mechanism. Complimentary to current available models, iPS technology offers unique opportunity to preserve and study cells at various disease stages that lead to hepatocellular carcinoma (HCC). Towards the goal of studying liver diseases using pluripotent stem cells, we have systematically improved reprogramming of human postnatal cells including primary hepatocytes.Importantly, we were able to differentiate iPS cells into early and mature hepatic cells. In this study, we propose to explore the possibility of modeling alcohol related HCC using patient- and disease- specific iPS cells. We plan to generate iPS cell lines from liver tissues of HCC patients with chronic alcohol consumption history. After characterization of these iPS cell lines, we will differentiate them into different stages of hepatic cells, using iPS cells from healthy donors as controls. We will test the hypothesis that the hepatic cells generated from diseased iPS cells possess certain characteristics of the disease (i.e. HCC). In particular, their ability to terminally differentiate, to proliferate and to undergo apoptosis will be determined. We will also initiate transplantation of these iPSC derived hepatic cells into immunodeficient mice to determine the in vivo activity of the cells. Completion of this study will help establish more human HCC relevant, innovative in vitro and in vivo models to systematically study the molecular mechanisms and the contribution of alcohol and other risk factors to different stages of hepatocarcinogenesis. PUBLIC HEALTH RELEVANCE: Completion of this study will help establish more human HCC relevant, innovative in vitro and in vivo models to systematically study the molecular mechanisms and the contribution of alcohol and other risk factors to different stages of hepatocarcinogenesis.
描述(由申请人提供):人类胚胎干细胞(ESC)和诱导多能干细胞(iPSC)研究的最新进展为开发修复和替换器官(包括肝脏)的新策略提供了前所未有的机会。利用来自病变组织的患者特异性iPS细胞建立疾病模型也是非常可取的,这些病变组织含有在其他组织或健康个体中不存在的体细胞突变。肝癌的发生被认为是一个多步骤的过程,涉及由酒精等环境因素引起的许多不同的遗传改变。累积效应最终导致肝细胞恶性转化。这一过程中每个步骤背后的分子事件尚不完全清楚,需要更好的模型系统来描述其机制。作为现有模型的补充,iPS技术为保存和研究导致肝细胞癌(HCC)的不同疾病阶段的细胞提供了独特的机会。为了实现利用多能干细胞研究肝脏疾病的目标,我们系统地改进了包括原代肝细胞在内的人类出生后细胞的重编程。重要的是,我们能够将iPS细胞分化为早期和成熟的肝细胞。在这项研究中,我们建议探索使用患者和疾病特异性iPS细胞模拟酒精相关HCC的可能性。我们计划从有慢性饮酒史的HCC患者的肝组织中产生iPS细胞系。在鉴定这些iPS细胞系后,我们将把它们分化成不同阶段的肝细胞,使用来自健康供体的iPS细胞作为对照。我们将验证由病变iPS细胞产生的肝细胞具有该疾病(即HCC)的某些特征的假设。特别是,它们最终分化、增殖和凋亡的能力将被确定。我们还将开始将这些iPSC衍生的肝细胞移植到免疫缺陷小鼠体内,以确定细胞的体内活性。本研究的完成将有助于建立更多与人类HCC相关的创新性体外和体内模型,系统研究酒精等危险因素在肝癌发生不同阶段的分子机制和贡献。

项目成果

期刊论文数量(10)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Efficient and Controlled Generation of 2D and 3D Bile Duct Tissue from Human Pluripotent Stem Cell-Derived Spheroids.
  • DOI:
    10.1007/s12015-016-9657-5
  • 发表时间:
    2016-08
  • 期刊:
  • 影响因子:
    4.8
  • 作者:
    Tian L;Deshmukh A;Ye Z;Jang YY
  • 通讯作者:
    Jang YY
Determination of Functional Activity of Human iPSC-Derived Hepatocytes by Measurement of CYP Metabolism.
通过测量 CYP 代谢测定人 iPSC 来源的肝细胞的功能活性。
In Vitro Modeling of Alcohol-Induced Liver Injury Using Human-Induced Pluripotent Stem Cells.
Hematopoietic cells as sources for patient-specific iPSCs and disease modeling.
造血细胞作为患者特异性 iPSC 和疾病模型的来源。
  • DOI:
    10.4161/cc.10.17.17180
  • 发表时间:
    2011
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Ye,Zhaohui;Liu,CyndiF;Jang,Yoon-Young
  • 通讯作者:
    Jang,Yoon-Young
Alcohol Increases Liver Progenitor Populations and Induces Disease Phenotypes in Human IPSC-Derived Mature Stage Hepatic Cells.
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Yoon Young Jang其他文献

Yoon Young Jang的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Yoon Young Jang', 18)}}的其他基金

Developing preclinical human iPSC-based HTS assays to identify therapeutic agents for biliary atresia
开发基于人类 iPSC 的临床前 HTS 检测,以确定胆道闭锁的治疗药物
  • 批准号:
    10434734
  • 财政年份:
    2020
  • 资助金额:
    $ 23.58万
  • 项目类别:
Developing preclinical human iPSC-based HTS assays to identify therapeutic agents for biliary atresia
开发基于人类 iPSC 的临床前 HTS 检测,以确定胆道闭锁的治疗药物
  • 批准号:
    10206130
  • 财政年份:
    2020
  • 资助金额:
    $ 23.58万
  • 项目类别:
Ultraminiaturized microfluidics-based drug toxicity screening platform using iPSC
使用 iPSC 的超小型基于微流体的药物毒性筛选平台
  • 批准号:
    8619264
  • 财政年份:
    2013
  • 资助金额:
    $ 23.58万
  • 项目类别:
DISEASE MODELING OF ALCOHOL RELATED HEPATOCELLULAR CARCINOMA USING PATIENT IPSCS
使用患者 IPSCS 对酒精相关肝细胞癌进行疾病建模
  • 批准号:
    8030259
  • 财政年份:
    2011
  • 资助金额:
    $ 23.58万
  • 项目类别:

相似海外基金

Uncovering the Role of Retinoic Acid Receptor Beta in Alcoholic Liver Diseases
揭示视黄酸受体β在酒精性肝病中的作用
  • 批准号:
    10019450
  • 财政年份:
    2019
  • 资助金额:
    $ 23.58万
  • 项目类别:
Uncovering the Role of Retinoic Acid Receptor Beta in Alcoholic Liver Diseases
揭示视黄酸受体β在酒精性肝病中的作用
  • 批准号:
    9896234
  • 财政年份:
    2019
  • 资助金额:
    $ 23.58万
  • 项目类别:
Alcoholic Liver Diseases: Damage, Repair and Stem Cell Regeneration
酒精性肝病:损伤、修复和干细胞再生
  • 批准号:
    7990196
  • 财政年份:
    2010
  • 资助金额:
    $ 23.58万
  • 项目类别:
Alcoholic Liver Diseases: Damage, Repair and Stem Cell Regeneration
酒精性肝病:损伤、修复和干细胞再生
  • 批准号:
    8299173
  • 财政年份:
    2010
  • 资助金额:
    $ 23.58万
  • 项目类别:
Alcoholic Liver Diseases: Damage, Repair and Stem Cell Regeneration
酒精性肝病:损伤、修复和干细胞再生
  • 批准号:
    8102173
  • 财政年份:
    2010
  • 资助金额:
    $ 23.58万
  • 项目类别:
Alcoholic Liver Diseases: Damage, Repair and Stem Cell Regeneration
酒精性肝病:损伤、修复和干细胞再生
  • 批准号:
    8494464
  • 财政年份:
    2010
  • 资助金额:
    $ 23.58万
  • 项目类别:
Alcoholic Liver Diseases: Damage, Repair and Stem Cell Regeneration
酒精性肝病:损伤、修复和干细胞再生
  • 批准号:
    8693870
  • 财政年份:
    2010
  • 资助金额:
    $ 23.58万
  • 项目类别:
Screening of food components for the prevention of alcoholic liver diseases and their application
预防酒精性肝病的食品成分筛选及其应用
  • 批准号:
    21500783
  • 财政年份:
    2009
  • 资助金额:
    $ 23.58万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Contribution of transforming growth factor-a to thr development of hepatic fibrosis in alcoholic liver diseases
转化生长因子-a对酒精性肝病肝纤维化发展的贡献
  • 批准号:
    09670560
  • 财政年份:
    1997
  • 资助金额:
    $ 23.58万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Immunological mechanism on the generation of alcoholic liver diseases
酒精性肝病发生的免疫学机制
  • 批准号:
    03670349
  • 财政年份:
    1991
  • 资助金额:
    $ 23.58万
  • 项目类别:
    Grant-in-Aid for General Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了